Currently, the whole world is dealing with the outbreak of the coronavirus. Several vaccines and medicines are being sought at the moment. Glenmark Pharmaceuticals to counter the coronavirus has introduced the antiviral drug Favipiravir under the brand name FabiFlu. Patients suffering from mild to moderate symptoms of the COVID-19 can use this drug to get themselves treated.
The Mumbai-based drug pharmaceuticals Glenmark had made this announcement on Saturday. It said that it has further received permission from the Comptroller and Auditor General of India (DGCI) to manufacture and market the drug. The company further added that the Favipiravir is the first oral drug to treat the coronavirus, which has been approved. The drug will be available in the market at a rate of around ₹103 per tablet.
The drug is said to be available in the form of 200 mg tablets at a maximum retail price (MRP) of ₹3,500 for a strip of 34 tablets. Glenn Saldanha, Chairperson and Managing Director of Glenmark Pharmaceuticals have said that the approval comes at a time when cases of coronavirus in India are growing faster than ever before. This, therefore, puts a lot of pressure on our healthcare system. He further opined that the availability of effective treatment like FabiFlu would help in reducing this pressure to a great extent.
This medication is said to be given to patients with mild to moderate symptoms. It has been recommended to take 1,800 mg twice in the first day and then 800 mg twice daily for 14 days. The tablet is being produced by the company in Baddi, Himachal Pradesh. The drug will be available through both hospitals and retail channels, according to Glenmark. Glenmark also said that the company has successfully developed Active Pharmaceutical Ingredients (APIs) and formulations for FabiFlu through its in-house research and development team.